| Identification | Back Directory | [Name]
N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine | [CAS]
881202-45-5 | [Synonyms]
CS-389
SerdeMetan
JNJ 26854165
JNJ-26854165, >=98%
Serdemetan(JNJ 26854165)
JNJ-26854165 (SerdeMetan)
JNJ 26854165; JNJ26854165; JNJ-26854165
N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine
N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-1,4-Benzene diamine
1,4-Benzenediamine, N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-
N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine ISO 9001：2015 REACH
N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine JNJ 26854165
JNJ 26854165 N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine | [EINECS(EC#)]
200-256-5 | [Molecular Formula]
C21H20N4 | [MDL Number]
MFCD16620518 | [MOL File]
881202-45-5.mol | [Molecular Weight]
328.41 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL in DMSO | [form ]
solid | [color ]
Light brown to brown | [InChI]
InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25) | [InChIKey]
CEGSUKYESLWKJP-UHFFFAOYSA-N | [SMILES]
C1(NCCC2C3=C(NC=2)C=CC=C3)=CC=C(NC2C=CN=CC=2)C=C1 |
| Hazard Information | Back Directory | [Uses]
JNJ 26854165 is a p53 activator and HDM2 ubiquitin ligase (MDM2) inhibitor. | [Biological Activity]
jnj-26854165, also named as serdemetan, is originally developed as an activator of p53, is now regarded as a novel oral human double minute-2 (hdm-2) ubiquitin ligase antagonist. it can increase the level of hdm-2 client proteins, such as p53, by inhibiting the association of hdm-2-client protein complex with the proteosome. it is demonstrated potent anti-proliferative and apoptosis-inducing activity of jnj-26854165 in a broad range of p53 wild type and mutant tumor models. in vivo, jnj-26854165 may induce important differences in efs distribution when comparing to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable all xenografts.j. tabernero, l. dirix, p. schoffski, a. cervantes, j. capdevila, j. baselga, l. van beijsterveldt, h. winkler, s. kraljevic and s. h. zhuang. phase i pharmacokinetic (pk) and pharmacodynamic (pd) study of hdm-2 antagonist jnj-26854165 in patients with advanced refractory solid tumors. journal of clinical oncology (meeting abstracts) may 2009 vol. 27 no. 15s 3514malcolm a. smith, richard gorlick, e. anders kolb, richard lock, hernan carol, john m. maris, stephen t. keir, christopher l. morton, c. patrick reynolds, min h. kang, janine arts, tarig bashir, michel janicot, raushan t. kurmasheva, peter j. houghton. initial testing of jnj-26854165 (serdemetan) by the pediatric preclinical testing program. pediatric blood & cancer. volume 59, issue 2, pages 329–332, august 2012. | [target]
HDM2 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|